2019-2020 Flu Vaccine Timeline

Recently, Sanofi Pasteur provided an update for the distribution of influenza vaccine for the 2019-2020 flu season.  Due to late-emerging A/H3N2 viruses that delayed the strain selection for the upcoming flu season, it is anticipated that the delivery of Sanofi Pasteur influenza vaccines will be approximately 3-4 weeks behind the shipping commitments previously communicated.  Sanofi Pasteur fully expects to manufacture and deliver every dose reserved by their customers, beginning with partial shipments to all customers in late-August or September, with all shipments completed by the end of November.

Each year, the World Health Organization (WHO) and U.S. Food and Drug Administration (FDA), with help from epidemiologists around the world, select the virus strains to be included in influenza vaccines for the upcoming season.  This year, due to late-emerging A/H3N2 viruses that circulated globally, the WHO and FDA decided to delay selection of the A/H3N2 strain by one month.  This allowed health authorities to collect additional data to help improve the match of the vaccine strain to the A/H3N2 strain anticipated to circulate during the 2019-2020 season.

Sanofi Pasteur fully supports this decision by health authorities to collect additional data and make a more informed selection.

If you have any questions, please feel free to contact the CPP office at 614-722-2145 or your Sanofi Pasteur representative.

Sanofi Pasteur’s Adacel (Tdap) Vaccine FDA Approved for Repeat Vaccination after 8 Years

The Food and Drug Administration recently approved the Adacel (Tdap) vaccine to be administered as soon as 8 years after a previous dose. Adacel, manufactured by Sanofi Pasteur, provides immunity to tetanus, diphtheria, and pertussis. The vaccine is approved for patients ages 10-64, and is available in a syringe made without natural rubber latex.

The current CDC recommendations for Tdap are as follows:

  • Adolescents should receive a single dose, preferably at age 11 or 12
  • All pregnant women should receive a single dose during pregnancy, preferably between weeks 27 and 36. By receiving this vaccine, pregnant mothers pass antibodies to their babies, reducing the risk of whooping cough.
  • Adults should receive a single dose of Tdap followed by a booster Td every 10 years.

FDA approval was based on clinical data from a study that showed no significant differences in adverse events when adults received Adacel versus Td 8-12 years after a previous dose of Adacel.  The approval of Adacel administration every 8 years provides more flexibility for physicians in both vaccine purchasing decisions and immunizations scheduling. Sanofi has provided study results to the CDC for consideration in future recommendations.

For more information or to purchase Adacel or any other immunization, visit our website or send us an email